Maria Nikiforou1, Joris Vanderlocht, Claire A Chougnet, Reint K Jellema, Daan R M G Ophelders, Mandy Joosten, Nico Kloosterboer, Birgit L M G Senden-Gijsbers, Wilfred T V Germeraad, Boris W Kramer, Tim G A M Wolfs. 1. *Department of Pediatrics, Maastricht University Medical Center (MUMC), Maastricht, the Netherlands; †School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; ‡School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, the Netherlands; §Department of Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Center (MUMC), Maastricht, the Netherlands; ||Division of Immunobiology, Department of Pediatrics, Cincinnati Children's Hospital Research Foundation, Cincinnati, Ohio; and ¶Department of Internal Medicine, Division of Haematology, Maastricht University Medical Center (MUMC), Maastricht, the Netherlands.
Abstract
BACKGROUND: Chorioamnionitis results from an infection of the fetal membranes and is associated with fetal adverse outcomes notably in the intestine. Using a translational ovine model, we showed that intra-amniotic exposure to inflammatory stimuli decreased the regulatory/effector T (Treg/Teff) cell balance in the gut, which was accompanied by intestinal inflammation and mucosal injury. We thus aimed to augment the Treg/Teff cell ratio in the fetal gut by prophylactic IL-2 treatment and evaluate whether it is sufficient to prevent chorioamnionitis-induced intestinal inflammation and mucosal injury. METHODS: Fetal sheep (122 d of gestation) were intra-amniotically exposed to lipopolysaccharide for 2 or 7 days with or without prophylactic IL-2 treatment (4 d). We evaluated the infiltration of inflammatory cells in the ileum and mesenteric lymph nodes. Cytokine gene expression was analyzed in fetal ileum and the inflammatory changes were correlated with gut wall integrity. RESULTS: IL-2 administration preferentially increased intestinal Treg cells and thus the Treg/Teff cell ratio. Prophylactic IL-2 treatment reduced the lipopolysaccharide-induced influx of neutrophils and CD3(+) T cells and decreased the messenger RNA levels of proinflammatory cytokines including IL-6 and IL-17 in the fetal ileum. Importantly, prophylactic IL-2 treatment prevented mucosal damage without inducing fetal adverse treatment outcomes. CONCLUSIONS: Our data show that prophylactic IL-2 treatment prevents fetal intestinal inflammation and mucosal injury in the context of experimental chorioamnionitis. Modulation of the Treg/Teff cell balance may contribute to the protective effects of IL-2.
BACKGROUND:Chorioamnionitis results from an infection of the fetal membranes and is associated with fetal adverse outcomes notably in the intestine. Using a translational ovine model, we showed that intra-amniotic exposure to inflammatory stimuli decreased the regulatory/effector T (Treg/Teff) cell balance in the gut, which was accompanied by intestinal inflammation and mucosal injury. We thus aimed to augment the Treg/Teff cell ratio in the fetal gut by prophylactic IL-2 treatment and evaluate whether it is sufficient to prevent chorioamnionitis-induced intestinal inflammation and mucosal injury. METHODS: Fetal sheep (122 d of gestation) were intra-amniotically exposed to lipopolysaccharide for 2 or 7 days with or without prophylactic IL-2 treatment (4 d). We evaluated the infiltration of inflammatory cells in the ileum and mesenteric lymph nodes. Cytokine gene expression was analyzed in fetal ileum and the inflammatory changes were correlated with gut wall integrity. RESULTS:IL-2 administration preferentially increased intestinal Treg cells and thus the Treg/Teff cell ratio. Prophylactic IL-2 treatment reduced the lipopolysaccharide-induced influx of neutrophils and CD3(+) T cells and decreased the messenger RNA levels of proinflammatory cytokines including IL-6 and IL-17 in the fetal ileum. Importantly, prophylactic IL-2 treatment prevented mucosal damage without inducing fetal adverse treatment outcomes. CONCLUSIONS: Our data show that prophylactic IL-2 treatment prevents fetal intestinal inflammation and mucosal injury in the context of experimental chorioamnionitis. Modulation of the Treg/Teff cell balance may contribute to the protective effects of IL-2.
Authors: Luise Klein; Daan R M G Ophelders; Daniel van den Hove; Maurits Damoiseaux; Bart P F Rutten; Chris P M Reutelingsperger; Leon J Schurgers; Tim G A M Wolfs Journal: Brain Behav Immun Health Date: 2022-05-02
Authors: Cesar M Rueda; Pietro Presicce; Courtney M Jackson; Lisa A Miller; Suhas G Kallapur; Alan H Jobe; Claire A Chougnet Journal: J Immunol Date: 2016-04-01 Impact factor: 5.422
Authors: Maria Nikiforou; Carolin Willburger; Anja E de Jong; Nico Kloosterboer; Reint K Jellema; Daan R M G Ophelders; Harry W M Steinbusch; Boris W Kramer; Tim Wolfs Journal: Mol Med Date: 2016-04-14 Impact factor: 6.354
Authors: Maria Nikiforou; Esmee M R Jacobs; Matthew W Kemp; Mathias W Hornef; Matthew S Payne; Masatoshi Saito; John P Newnham; Leon E W Janssen; Alan H Jobe; Suhas G Kallapur; Boris W Kramer; Tim G A M Wolfs Journal: Sci Rep Date: 2016-07-14 Impact factor: 4.379
Authors: Monique G M Willems; Matthew W Kemp; Laura A Fast; Nick M M Wagemaker; Leon E W Janssen; John P Newnham; Matt S Payne; Owen B Spiller; Suhas G Kallapur; Alan H Jobe; Tammo Delhaas; Boris W Kramer; Tim G A M Wolfs Journal: PLoS One Date: 2017-06-30 Impact factor: 3.240
Authors: Charlotte van Gorp; Ilse H de Lange; Kimberly R I Massy; Lilian Kessels; Alan H Jobe; Jack P M Cleutjens; Matthew W Kemp; Masatoshi Saito; Haruo Usada; John Newnham; Matthias Hütten; Boris W Kramer; Luc J Zimmermann; Tim G A M Wolfs Journal: Int J Mol Sci Date: 2021-02-16 Impact factor: 5.923
Authors: Marcelo Farias-Jofre; Roberto Romero; Jose Galaz; Yi Xu; Li Tao; Catherine Demery-Poulos; Marcia Arenas-Hernandez; Gaurav Bhatti; Zhenjie Liu; Naoki Kawahara; Tomi Kanninen; Zachary Shaffer; Tinnakorn Chaiworapongsa; Kevin R Theis; Adi L Tarca; Nardhy Gomez-Lopez Journal: Inflamm Res Date: 2022-04-21 Impact factor: 6.986